This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

One-Year Study Demonstrates Vision-Sciences' EndoSheath Technology Protects Against Bacterial Contamination Of Bronchoscopes

Stocks in this article: VSCI

ORANGEBURG, N.Y., Oct. 22, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc. (Nasdaq:VSCI) announced today that the detailed findings of a twelve-month evaluation of its EndoSheath ® technology in the critical care setting were presented by Dr. Flavia Petrini, Professor of Anaesthesia and Intensive Care, Università Gabriele d'Annunzio Chieti-Pescara (Italy), in a scientific poster at the 67 th National Congress of the Società Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI).

Of the 53 bronchoscopy cases conducted there were no cases of bacterial contamination of bronchoscopes, excluding two deliberate contaminations by the bronchoscopists for control purposes. "These highly positive study outcomes add to the growing body of data on the microbiology validation of our EndoSheath technology, and further support the advantages of using our sterile, disposable technology over conventional, difficult to clean and disinfect endoscopes," stated Howard Zauberman, Interim Chief Executive Officer of Vision-Sciences.

This study was conducted by researchers at the Università Gabriele d'Annunzio Chieti-Pescara Hospital Intensive Care Unit (ICU) to examine the impact of the EndoSheath technology on reducing the bacterial contamination of the bronchoscopes and the potential for eliminating the need of routine high-level disinfection (HLD) in reprocessing.  During the twelve-month study period, investigators used Vision-Sciences' bronchoscope with EndoSheath technology to perform bronchoscopic procedures (n=53) including bronchial aspirate (BAS) (n=19), bronchoalveolar lavage (BAL) (n=31), and percutaneous tracheostomy (PCT) (n=3).  The device was cultured three times for each procedure: before the application of the EndoSheath; after the procedure and removal of the EndoSheath; and, after enzymatic cleaning, drying and disinfection with 70% ethanol. A sterile pledget was wiped on the entire surface of the insertion tube and a second one on the entire surface of the control head. Both were placed in sterile specimen containers for culture. 

The operator deliberately contaminated two (3.8%) results for control purposes by touching several areas and other devices in the ICU. As expected, these two results tested positive for bacterial contamination with Staphylococcus (CoNS) or Sphingomonas paucimobilis. The remaining 51 procedures (96.2%) tested negative for bacterial contamination.

Overall performance of the device was also measured by the bronchoscopist after each procedure using a semi-quantitative linear score (0=minimum; 5=maximum). The device was judged positively for performance in terms of visualization (defined by clarity of the image and brightness), suitability (defined by general comfort and easiness of use) and function usefulness (defined by potency of aspiration and injection, tip movements). The mean scores for these criteria were as follows:

Visualization 3.9 (95% CI: 2.2-5.6)
Suitability 3.0 (95% CI: 1.6-4.4)
Function usefulness 3.1 (95% CI: 1.7-4.5)

A comparative study is planned to confirm this data on bacterial reduction.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,030.21 +6.04 0.03%
S&P 500 2,081.88 -0.29 -0.01%
NASDAQ 4,773.4720 +8.0480 0.17%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs